Drugs

The Future of the Quinolones
pp. 1-5(5)
Author: Andriole V.T.

Mode of Action of Fluoroquinolones
pp. 6-10(5)
Author: Hooper D.C.

Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998
pp. 11-18(8)
Author: Piddock L.J.V.

Activity of Quinolones Against Mycobacteria
pp. 19-22(4)
Author: Jacobs M.R.

Activity of Newer Fluoroquinolones In Vitro Against Gram-Positive Bacteria
pp. 23-28(6)
Author: Eliopoulos G.M.

Pharmacokinetics and Pharmacodynamics of Fluoroquinolones
pp. 29-36(8)
Author: Turnidge J.

Toxicity of Quinolones
pp. 37-42(6)
Authors: Stahlmann R.; Lode H.

Fluoroquinolones in Paediatrics
pp. 43-48(6)
Authors: Jafri H.S.; McCracken G.H.J.

Quinolones in the Aged
pp. 49-51(3)
Author: Nicolle L.E.

Quinolones in the Treatment of Typhoid Fever
pp. 52-54(3)
Author: Erdal Akalin H.

Quinolone Use in the Developing World: State of the Art
pp. 55-59(5)
Author: Tupasi T.E.

Quinolone Activity Against Anaerobes
pp. 60-64(5)
Author: Appelbaum P.C.

Effect of Quinolones on Intestinal Ecology
pp. 65-70(6)
Authors: Edlund C.; Nord C.E.

Cost Effectiveness of Quinolones in Hospitals and the Community
pp. 71-77(7)
Author: Davey P.

Activity of Quinolones Against Chlamydia pneumoniae
pp. 78-81(4)
Author: Hammerschlag M.R.

Fluoroquinolone Treatment of Skin and Skin Structure Infections
pp. 82-84(3)
Author: Karchmer A.W.

Use of Quinolones in Osteomyelitis and Infected Orthopaedic Prosthesis
pp. 85-91(7)
Authors: Lew D.P.; Waldvogel F.A.

Quinolones in Sexually Transmitted Diseases: State of the Art
pp. 92-95(4)
Author: Ridgway G.L.

The Quinolones and Renal Infection
pp. 96-98(3)
Author: Ronald A.

Newer Quinolones in the Long Term Prophylaxis of Recurrent Urinary Tract Infections (UTI)
pp. 99-102(4)
Authors: Krcméry S.; Hromec J.; Tvrdikova M.; Hassan M.; Gulla D.

Outcome of Antibiotic Therapy with Ciprofloxacin in Chronic Bacterial Prostatitis
pp. 103-106(4)
Authors: Weidner W.; Ludwig M.; Brähler E.; Schiefer H.G.

Antimicrobial Activity of Gatifloxacin Against Campylobacter jejuni and Anaerobic Bacteria
pp. 107-109(3)
Authors: Erwin M.E.; Jones R.N.; Barrett M.S.; Pfaller M.A.; Hayward C.L.; Doern G.V.

Antianaerobic Activity of Grepafloxacin Compared with Ofloxacin, Ciprofloxacin, Clindamycin, Metronidazole and 5 -Lactams
pp. 110-112(3)
Authors: Dubreuil L.; Singer E.; Odou M.F.; Leblanc F.

Antianaerobic Activity of Gatifloxacin
pp. 113-116(4)
Authors: Ednie L.M.; Jacobs M.R.; Appelbaum P.C.

Grepafloxacin vs Pneumococci Resistant to Fluoroquinolones by a Putative Efflux Mechanism
pp. 117-118(2)
Authors: Brenwald N.P.; Gill M.J.; Wise R.

Mutations to Quinolone Resistance in Pseudomonas aeruginosa and Enterococcus faecium
pp. 119-120(2)
Authors: Jalal S.; El Amin N.; Gotoh N.; Wretlind B.

Activity of Trovafloxacin Against Topoisomerases and GyrA/GrlA Mutants of Staphylococcus aureus
pp. 121-122(2)
Authors: Gootz T.D.; Zaniewski R.P.; Haskell S.L.; Kaczmarek F.S.; Maurice A.E.

Ofloxacin Selects First-Step ParC Mutations in Mycoplasma hominis Whereas Sparfloxacin Selects for First-Step GyrA Mutations
pp. 123-124(2)
Authors: Kenny G.E.; Young P.A.; Cartwright F.D.; Sjostrom K.E.; Huang W.M.

Fluoroquinolone Resistance Mutations in the DNA Topoisomerase II Genes of Viridans Group Streptococci Clinical Isolates
pp. 125-127(3)
Authors: Balas D.; González I.; Georgiou M.; Alcaide F.; Liñares J.; De La Campa A.G.

Nosocomial Superinfections with Gram-Negative Pathogens and Quinolone Resistance after Treatment with Ciprofloxacin vs Ofloxacin
pp. 128-129(2)
Authors: Carmeli Y.; Samore M.H.

Resistant Mutants of Staphylococcus aureus with Ofloxacin in Comparison with Ciprofloxacin
pp. 130-131(2)
Authors: Rio Y.; Jurin F.; Didion J.

Mechanisms and Frequency of Resistance to Moxifloxacin in Comparison with Ciprofloxacin in Staphylococcus aureus
pp. 132-133(2)
Authors: Ince D.; Aras R.; Hooper D.C.

Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison with Ciprofloxacin in Staphylococcus aureus
pp. 134-135(2)
Authors: Ince D.; Aras R.; Hooper D.C.

Mutational Resistance to Quinolones in Staphylococci: Trovafloxacin vs Ciprofloxacin
pp. 136-137(2)
Authors: Thomson K.S.; Moland E.S.; Sanders C.C.

Comparative In Vitro Activity of Grepafloxacin Against Selected Mutants and Clinical Isolates
pp. 138-140(3)
Authors: Soussy C.J.; Leblanc F.

Synergistic Activity of Trovafloxacin with Other Agents
pp. 141-143(3)
Authors: Visalli M.A.; Bajaksouzian S.; Jacobs M.R.; Appelbaum P.C.

Antimicrobial Activity of Moxifloxacin and Levofloxacin Photodegradation Products
pp. 144-145(2)
Authors: Tobin C.M.; Sunderland J.; MacGowan A.P.; Hedges A.J.; White L.O.

Comparative Postantibiotic Effect of Sitafloxacin and Trovafloxacin on Methicillin-Resistant Staphylococcus aureus
pp. 146-148(3)
Authors: Giamarellos-Bourboulis E.J.; Grecka P.; Sambatakou H.; Chryssouli Z.; Giamarellou H.

Synergistic In Vitro Activity of Clinafloxacin
pp. 149-150(2)
Authors: Perri M.B.; Zervos M.J.

Comparative Antibiotic Activity Versus Vancomycin Intermediate-Susceptible Staphylococcus aureus
pp. 151-153(3)
Authors: Huband M.D.; Cohen M.A.; Gage J.W.; VanderRoest S.R.

Activity of Trovafloxacin Against Micro-Organisms Isolated from Diabetic Patients with Lower Extremity Infections
pp. 154-155(2)
Authors: Weiss K.; Laverdiére M.; Restieri C.; Poirier L.

Moxifloxacin: Comparative Inhibitory Bactericidal Activity Against Susceptible and Multidrug-Resistant Gram-Positive Bacteria
pp. 156-159(4)
Authors: Speciale A.; Aleo G.; La Ferla K.; Musumeci R.; Caccamo F.; Nicoletti G.

Antistaphylococcal Activity of Moxifloxacin
pp. 160-161(2)
Author: Dalhoff A.

Antimicrobial Activity of Gatifloxacin Tested Against 1676 Gram-Positive Cocci Resistant to Ciprofloxacin: A Multicentre Organism Sample from North and Latin America
pp. 162-163(2)
Authors: Jones R.N.; Pfaller M.A.; Doern G.V.; Beach M.

Antistreptococcal Activity of Gatifloxacin
pp. 164-165(2)
Authors: Jones R.N.; Johnson D.M.; Erwin M.E.; Beach M.L.; Biedenbach D.J.

Antibacterial Activity of Gatifloxacin in Obstetrics and Gynaecology
pp. 166-168(3)
Authors: Izumi K.; Mikamo H.; Kawazoe K.; Tamaya T.

In Vitro Antibacterial Activities of Gatifloxacin (AM-1155) Against Clinical Pathogens Recently Isolated from Various Infections
pp. 169-170(2)
Authors: Tsurumaki Y.; Manda H.; Takei M.; Oomori Y.

Ofloxacin Photodegradation Products Possess Antimicrobial Activity
pp. 171-172(2)
Authors: Sunderland J.; Tobin C.M.; White L.O.; MacGowan A.P.; Hedges A.J.

Antimicrobial Spectrum of Gatifloxacin in the SENTRY Program
pp. 173-175(3)
Authors: Jones R.N.; Pfaller M.A.; Doern G.V.; Beach M.

Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Dilution and Disk Diffusion Methods
pp. 176-177(2)
Authors: Kugler K.C.; Jones R.N.; Biedenbach D.J.; Erwin M.E.; Pfaller M.A.; Doern G.V.

In Vitro Antimicrobial Activity of Gatifloxacin Against N. gonorrhoeaeand H. influenzae
pp. 178-179(2)
Authors: Biedenbach D.J.; Jones R.N.; Beach M.L.; Barrett M.S.; Johnson D.M.; Pfaller M.A.; Doern G.V.

Antimicrobial Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia spp.
pp. 180-181(2)
Authors: Biedenbach D.J.; Jones R.N.; Marshall S.A.; Johnson D.M.; Croco M.A.T.

Activity of Moxifloxacin Against Klebsiella pneumoniae
pp. 182-183(2)
Author: Dalhoff A.

Serum Bactericidal Activity of Moxifloxacin
pp. 184-185(2)
Authors: Dalhoff A.; Stass H.; Obertegger S.

Current Activity of Ciprofloxacin Against Gram-Negative Bacilli in the United States
pp. 186-187(2)
Authors: Thornsberry C.; Marsilio M.K.; Jones M.E.; Tomfohrde K.M.; Heller B.H.; Piazza G.; Sahm D.F.

Comparison of In Vitro Activity of Trovafloxacin, Ciprofloxacin and Ceftazidime on Clinical Isolates
pp. 188-189(2)
Authors: Öngen B.; Kaygusuz A.; Öksuz L.; Töreci K.

Comparative Activity of 7 Quinolones Against Non-Glucose Fermenting Gram-Negative Bacilli Isolated from Cancer Patients
pp. 190-192(3)
Authors: Balakrishnan M.; Mago H.; LeBlanc B.; Rolston K.V.I.

Susceptibility of Anaerobic Gram-Negative Rods to Trovafloxacin
pp. 193-194(2)
Authors: Litterio M.; Castello L.; Rollet A.; Di Martino A.; Greco G.; Canigia L.F.; Fernandez M.I.; Predari S.; Bianchini H.

Comparative In Vitro Activity of Trovafloxacin Against Gram-Positive and Gram-Negative Clinical Isolates from Argentina
pp. 195-199(5)
Authors: Dufranc L.; Sucari A.; Lorenzo H.; Stepanik D.; de Vedia L.; Casellas J.M.; López H.; Tomé G.; Clara L.; Marín M.; Rossi A.; Galas M.; Smayevsky J.

In Vitro Activity of Trovafloxacin, Ciprofloxacin, Azithromycin, Roxithromycin and Clarithromycin Against 355 Clinical Isolates with Different Resistance Patterns
pp. 200-202(3)
Authors: Casellas J.M.; Tome G.; Gilardoni M.; Pagniez G.; Ivanovic S.

Trovafloxacin: In Vitro Activity and Comparison with Other Antibacterial Agents: WHONET-Resisnet Program, 1998
pp. 203-206(4)
Authors: Rossi A.; Tokumoto M.; Galas M.; Guelfand L.; Lopardo H.

Activity of Trovafloxacin Against P. aeruginosa, Methicillin-Resistant S. aureus and Pneumococci
pp. 207-208(2)
Authors: Kelly L.M.; Jacobs M.R.; Appelbaum P.C.

Susceptibility of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients to Ciprofloxacin
pp. 209-210(2)
Authors: Bauernfeind A.; Jungwirth R.; Ratjen F.

Susceptibility of Pseudomonas aeruginosa to Levofloxacin and Trovafloxacin Based on MICs for Ciprofloxacin and Ofloxacin
pp. 211-213(3)
Author: Waites K.B.

Susceptibility of Stenotrophomonas maltophilia to Moxifloxacin, Trovafloxacin, Ofloxacin and Ciprofloxacin
pp. 214-216(3)
Authors: Hawley H.B.; Polenakovik H.M.; Czachor J.S.; Mueller S.S.

Clinafloxacin Antibacterial Activity
pp. 217-221(5)
Authors: Ednie L.M.; Jacobs M.R.; Appelbaum P.C.

Single Dose Pharmacokinetics of the R- and S-Enantiomers of Gatifloxacin in Volunteers
pp. 222-224(3)
Authors: Stahlberg H.-J.; Goehler K.; Guillaume M.; Mignot A.

Basic Pharmacokinetics of Moxifloxacin
pp. 225-226(2)
Authors: Stass H.; Kubitza D.

Absorption and Bioavailability of Moxifloxacin
pp. 227-228(2)
Author: Stass H.

Distribution and Tissue Penetration of Moxifloxacin
pp. 229-230(2)
Author: Stass H.

Metabolism and Excretion of Moxifloxacin
pp. 231-232(2)
Author: Stass H.

Pharmacokinetics of Moxifloxacin in Special Populations
pp. 233-234(2)
Authors: Stass H.; Lettieri J.

Interaction Profile of Moxifloxacin
pp. 235-236(2)
Authors: Stass H.; Kubitza D.

Advances in Bioanalytical Methodology Used to Characterise Clinical Pharmacokinetics of Moxifloxacin
pp. 237-238(2)
Authors: Möller J.-G.; Stass H.; Mück W.

Determination of Moxifloxacin by HPLC and Bioassay: Practicality and Limitations
pp. 239-241(3)
Authors: Dalhoff A.; Stass H.

Impact of Neutropenia on Tissue Penetration of Moxifloxacin and Sparfloxacin in Infected Mice
pp. 242-245(4)
Authors: Garraffo R.; Roptin C.; Boudjadja A.

Effect of Age on Clinafloxacin Pharmacokinetics in Healthy Volunteers
pp. 246-247(2)
Authors: Randinitis E.J.; Abel R.; Bron N.J.; Hounslow N.J.; Rausch G.; Vassos A.B.

Effect of Clinafloxacin on the Pharmacokinetics of Theophylline and Caffeine
pp. 248-249(2)
Authors: Randinitis E.J.; Koup J.R.; Rausch G.; Vassos A.B.

Clinafloxacin Pharmacokinetics in Renal Patients
pp. 250-251(2)
Authors: Randinitis E.J.; Koup J.R.; Rausch G.; Bron N.J.; Hounslow N.J.; Vassos A.B.; Sedman A.J.

Pharmacokinetics of Oral and Intravenous Clinafloxacin
pp. 252-253(2)
Authors: Randinitis E.J.; Brodfuehrer J.; Vassos A.B.

Drug Interaction Studies with Clinafloxacin and Probenecid, Cimetidine, Phenytoin and Warfarin
pp. 254-255(2)
Authors: Randinitis E.J.; Koup J.R.; Bron N.J.; Hounslow N.J.; Rausch G.; Abel R.; Vassos A.B.; Sedman A.J.

Effects of Food and Antacid on the Pharmacokinetics of Clinafloxacin
pp. 256-257(2)
Authors: Alvey C.; Randinitis E.J.; Rausch G.; Vassos A.B.

In Vitro Pharmacodynamic and Pharmacokinetic Aspects of THP-1 Human Monocyte Uptake, Distribution and Efflux of C-Grepafloxacin under Different Conditions
pp. 258-259(2)
Authors: Dietrich M.A.; Butts J.D.; Alford P.; Ives T.J.; Hall I.H.

Clinafloxacin in Serious Infections Caused by Multiply Resistant Pathogens
pp. 260-262(3)
Authors: Tack K.J.; Eiseman I.; Zervos M.

Ciprofloxacin in the Treatment of Nosocomial Meningitis in Neonates and Infants: A Report of 12 Cases
pp. 263-265(3)
Authors: Krcméryová T.; Filka J.; Krcméry V.J.; Uher J.; Kurak H.; agát T.; Tuharsky J.; Novák I.; Ur banová T.; Kralinsky K.; Dluholucky S.

Bacteraemia and Fungaemia During Ofloxacin Prophylaxis in Cancer Patients
pp. 266-268(3)
Authors: Krcmeryjr V.; Trupl J.; Demitrovicova A.; Kukuckova E.; Studena M.; Mateicka F.

Pharmacodynamics of Trovafloxacin vs Ceftriaxone in Streptococcus pneumoniae
pp. 269-270(2)
Authors: Lister P.D.; Sanders C.C.

Use of Intravenous Ciprofloxacin in a Canadian Medical Centre
pp. 271-272(2)
Authors: Karlowsky J.A.; Gin A.S.; Cooper R.; Hoban D.J.; Zhanel G.G.

A Critical Pathway for the Treatment of Community-Acquired Pneumonia
pp. 273-275(3)
Authors: Marrie T.J.; Lau C.Y.; Wheeler S.L.; Wong C.J.; Vandervoort M.K.; Feagan B.G.

The Microbiological Eradication Rate of First-Line Antibiotic Treatment is a Key Cost Driver in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis
pp. 276-277(2)
Authors: Lacey L.F.; Volmer T.; Harris A.M.

The Clinical Failure Rate of First-Line Antibiotic Treatment is the Key Cost Driver in Community-Acquired Lower Respiratory Tract Infections
pp. 278-279(2)
Authors: van Barlingen H.J.J.; Volmer T.; Lacey L.F.

Efficacy of Gatifloxacin in Pneumococcal Respiratory Infection
pp. 280-281(2)
Authors: Soejima R.; Saito A.

Ofloxacin Once Daily Versus Twice Daily in Community-Acquired Pneumonia
pp. 282-283(2)
Authors: Krcméry Jr V.

Oral Trovafloxacin Versus Intravenous Cefoxitin in Elective Hysterectomy
pp. 284-285(2)
Author: Luke D.R.

Alatrofloxacin Versus Cefotetan in Prophylaxis of Colorectal Surgery
pp. 286-287(2)
Author: Luke D.R.

Comparison of the Efficacy and Safety of Once-Daily Oral Trovafloxacin and 3-Times-Daily Amoxicillin/Clavulanic Acid for the Treatment of Complicated Skin and Soft-Tissue Infections
pp. 288-290(3)
Author: Daniel R.

Once-Daily Oral Trovafloxacin in the Treatment of Diabetic Foot Infections: Results of an Open-Label, Noncomparative, Multicentre Trial
pp. 291-292(2)
Author: Daniel R.

Trovafloxacin Once Daily vs Flucloxacillin Four Times Daily in the Treatment of Uncomplicated Skin and Skin-Structure Infections
pp. 293-294(2)
Author: Daniel R.

Comparison of Intravenous to Oral Trovafloxacin vs Intravenous Imipenem/Cilastatin to Oral Amoxicillin/Clavulanic Acid in Complicated Intra-Abdominal Infections
pp. 295-297(3)
Author: Luke D.R.

Failure of Alatrofloxacin in Patients with Deep Surgical Infection
pp. 298-300(3)
Authors: Gandhi V.; Patel K.; Sordillo E.M.

Oral Trovafloxacin vs Oral Cefuroxime ± Erythromycin in Community-Acquired Pneumonia
pp. 301-303(3)
Author: Peterson J.

Trovafloxacin vs High Dose Amoxicillin in the Treatment of Community-Acquired Bacterial Pneumonia: Results of a Multicentre, Double-Blind Study
pp. 304-305(2)
Author: Daniel R.

Trovafloxacin vs Amoxicillin/Clavulanic Acid in the Treatment of Acute Exacerbations of Chronic Obstructive Bronchitis
pp. 306-308(3)
Author: Daniel R.

IV-to-Oral Switch Therapy with Trovafloxacin Compared with IV Ceftazidime/Oral Ciprofloxacin in the Treatment of Nosocomial Pneumonia
pp. 309-311(3)
Authors: Bassaris H.P.; Hopkins D.W.; Daniel R.

Trovafloxacin vs Clarithromycin in Patients with Ambulatory Community-Acquired Pneumonia
pp. 312-314(3)
Author: Hopkins D.W.

Trovafloxacin vs Amoxicillin in the Oral Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis
pp. 315-317(3)
Author: Daniel R.

Trovafloxacin vs Ceftriaxone/Cefpodoxime ± Erythromycin in Hospitalised Community-Acquired Pneumonia
pp. 318-319(2)
Authors: Hopkins D.W.; Daniel R.

Oral Trovafloxacin Compared with Amoxicillin (plus Optional Erythromycin) for the Treatment of Mild to Moderate Community-Acquired Pneumonia
pp. 320-322(3)
Author: Daniel R.

Trovafloxacin vs Ciprofloxacin ± Clindamycin/Metronidazole in Patients with Nosocomial Pneumonia
pp. 323-325(3)
Authors: Hopkins D.W.; Daniel R.

Oral Levofloxacin Compared with Clarithromycin in Acute Sinusitis
pp. 326-327(2)
Authors: Lasko B.; Lau C.Y.; Anstey R.J.; St-Pierre C.; Martel A.Y.; Diaz-Mitoma F.

Ciprofloxacin and Cefuroxime Axetil in Acute Community-Acquired Rhinosinusitis
pp. 328-329(2)
Authors: Weis M.; Hendrick K.; Gravelle K.; Tillotson G.

Are the Fluoroquinolones Comparable in the Treatment of Urinary Tract Infections?
pp. 330-334(5)
Author: Naber K.G.

Effects of Ciprofloxacin in Urinary Tract Infections Using Different Dose Regimens
pp. 335-338(4)
Author: Janicki K.

Efficacy and Safety of Ofloxacin in Ureaplasma Infections of the Upper Urinary Tract
pp. 339-340(2)
Authors: Dimitrakov J.D.; Dimitrakov D.J.; Rawadi G.

Ciprofloxacin in the Treatment of Chronic Bacterial Prostatitis
pp. 341-343(3)
Authors: Naber K.G.; Focht J.; Busch W.

Activity of Moxifloxacin Against Moraxella catarrhalis and Atypicals
pp. 344-345(2)
Author: Dalhoff A.

The Activity of Fluoroquinolones and Other Antimicrobial Agents Against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
pp. 346-348(3)
Authors: Thornsberry C.; Ogilvie P.; Holley H.P.; Hickey M.L.; Jones M.E.; Critchley I.A.; Sahm D.F.

Activity of Moxifloxacin Against H. influenzae and H. parainfluenzae
pp. 349-350(2)
Author: Dalhoff A.

Antipneumococcal Activity of Moxifloxacin
pp. 351-353(3)
Author: Dalhoff A.

Inhibition of Pneumococcal Topoisomerases by Sitafloxacin
pp. 354-355(2)
Authors: Morrissey I.; George J.T.

Serum Bactericidal Activity of Trovafloxacin Against Drug-Resistant Respiratory Pathogens
pp. 356-357(2)
Author: Stein G.E.

Grepafloxacin Activity Against 3000 Canadian Respiratory Tract Pathogens
pp. 358-360(3)
Authors: Hoban D.J.; Zhanel G.G.; Palatnick L.; Weshnoweski B.; Vercaigne L.; Karlowsky J.A.

Surveillance of Antimicrobial Resistance among Respiratory Tract Pathogens in the United States, 1997 to 1998
pp. 361-363(3)
Authors: Thornsberry C.; Hickey M.L.; Kahn J.; Mauriz Y.; Sahm D.F.

International Surveillance of Susceptibility to Levofloxacin and Other Agents among Respiratory Pathogens
pp. 364-365(2)
Authors: Thornsberry C.; Hickey M.L.; Jones M.E.; Critchley I.A.; Park G.P.; Sahm D.F.

Levofloxacin and Clarithromycin Antipneumococcal Activity
pp. 366-368(3)
Authors: Clark C.L.; Jacobs M.R.; Appelbaum P.C.

Antipneumococcal Activity of Gatifloxacin by Time-Kill Methodology
pp. 369-371(3)
Authors: Lin G.; Jacobs M.R.; Appelbaum P.C.

Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC
pp. 372-373(2)
Authors: Hoellman D.B.; Jacobs M.R.; Appelbaum P.C.

Susceptibility of Respiratory Pathogens to Grepafloxacin
pp. 374-375(2)
Authors: Cisterna R.; Gobernado M.; García Rodríguez J.A.

Bactericidal Activity of Grepafloxacin Against Respiratory Pathogens
pp. 376-377(2)
Authors: Daschner F.; Frank U.; Huber K.

Postantibiotic Effect of Levofloxacin Against Pneumococci
pp. 378-380(3)
Authors: Spangler S.K.; Lin G.; Jacobs M.R.; Appelbaum P.C.

MICs for Streptococcus pneumoniae with Reduced Penicillin Susceptibility
pp. 381-382(2)
Authors: Luna V.A.; Roberts M.C.

Development of High Level Quinolone Resistance in Streptococcus pneumoniae During Sequential Quinolone Therapy
pp. 383-384(2)
Authors: Suh B.; Lorber B.; Gelone S.; Truant A.L.; Gootz T.D.

Chondrotoxicity and Target Tissue Kinetics of Ofloxacin in Immature Rats after Multiple Doses
pp. 385-387(3)
Authors: Schwabe R.; Lozo E.; Baumann-Wilschke I.; Stahlmann R.

Chondrotoxicity of Ciprofloxacin in Immature Beagle Dogs
pp. 388-389(2)
Authors: Stahlmann R.; Kühner S.; Shakibaei M.; Schwabe R.; van Sickle D.

Effects of Ofloxacin on the Ultrastructure of Achilles Tendon in Rats
pp. 390-392(3)
Authors: Shakibaei M.; Pfister K.; Schwabe R.; Stahlmann R.

Supplementation with Magnesium and Tocopherol Diminishes Quinolone-Induced Chondrotoxicity in Immature Rats
pp. 393-394(2)
Authors: Stahlmann R.; Schwabe R.; Pfister K.; Lozo E.; Shakibaei M.; Vormann J.

Clinical Safety Profile of Grepafloxacin
pp. 395-396(2)
Authors: Lode H.; Vogel F.; Elies W.

Phototoxic Potential of Gatifloxacin, a New Fluoroquinolone Antimicrobial
pp. 397-399(3)
Authors: Ferguson J.; McEwen J.; Gohler K.; Mignot A.; Watson D.

Comparative Antimycobacterial Activity of BAY 12-8039 and Gatifloxacin
pp. 400-401(2)
Author: Saito H.

Fluoroquinolones in the Treatment of Atypical Mycobacterial Infections in AIDS
pp. 402-403(2)
Authors: Gatti G.; Bassetti M.; Bassetti D.; Bussolino C.; Cruciani M.; Collidà A.; Del Bono V.; Di Biagio A.; Mazzarello G.; Pontali E.; Mantero E.

In Vitro Activity of Grepafloxacin Against Chlamydia trachomatis
pp. 404-405(2)
Authors: Poutiers F.; Dessus-Babus S.; Leblanc F.; Bébéarr C.; de Barbeyrac B.

Susceptibility of Mycoplasma hominis to Moxifloxacin by E-Test and Agar Dilution
pp. 406-407(2)
Authors: Waites K.B.; Canupp K.C.; Kenny G.E.

Therapeutic Effects of Sitafloxacin in Rat Uterine Endometritis
pp. 408-409(2)
Authors: Mikamo H.; Kawazoe K.; Izumi K.; Tamaya T.

Pharmacodynamics of Trovafloxacin and Ciprofloxacin Against Ciprofloxacin- Resistant Viridans Streptococci
pp. 410-411(2)
Authors: Lister P.D.; Sanders C.C.

Therapeutic Efficacy of Sitafloxacin Against Pseudomonas aeruginosa in a Rat Model of Urinary Tract Infection
pp. 412-414(3)
Authors: Kurosaka Y.; Ishida Y.; Yamamura E.; Otani T.; Kumon H.

Quinolone Activity Against Respiratory Pathogens
pp. 415-416(2)
Author: Wiedemann B.

Pharmacodynamic Activity of Levofloxacin in an In Vitro Model Against Gram-Positive and Gram-Negative Bacteria
pp. 417-419(3)
Authors: Wiedemann B.; Pfeil E.